Orion Corporation
Update in progressORNAV.HE (Helsinki)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - General
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Europe, North America, and globally. Its portfolio includes Nubeqa, Entacapone/Stalevo/Comtess/Comtan, Burana, Divina, Simdax, Fareston, Quetiapine products, Trexan, Easyhaler lines, and Dexdor, Dexmedetomidine. It also offers asthma/COPD inhalers, veterinary drugs, APIs, contract manufacturing, and self-care products online, with TNX-103 and darolutamide licenses. Founded 1917 in Espoo.
Company score
- Sentiment
- 0.13
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.19
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketHelsinki (HEL)
- LocationFinland
- CEODr. Liisa Hurme Ph.D.
- Founded1917
- Employees4,000
- Websitewww.orionpharma.com
Identifiers
- ISINFI0009014369